In spite of its delayed timeline for US market entry, Novartis AG is hoping its strategy around inclisiran in atherosclerotic cardiovascular disease (ASCVD) – focusing on adherence, access and affordability – can ensure sufficient uptake of the twice-yearly PCSK9 inhibitor if it wins Food and Drug Administration approval.
The company has been busy at work developing a buy-and-bill infrastructure, as well as a network of injection centers, and...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
